Aprotinin is useful as a hemostatic agent in cardiopulmonary surgery: No

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 9, 2006, Pages 1879-1881

  Karkouti, Keyvan ^a   Beattie, W S ^b  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; APROTININ; HEMOSTATIC AGENT; PLACEBO; TRANEXAMIC ACID;

ARTICLE; BLEEDING; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; DRUG PREFERENCE; DRUG SAFETY; HEART INFARCTION; HEMOSTASIS; HUMAN; KIDNEY FAILURE; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; STROKE;

APROTININ; BLOOD LOSS, SURGICAL; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; HEMORRHAGE; HEMOSTATICS; HUMANS;

EID: 33747183945     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.02106.x     Document Type: Article

References (14)

1. Fergusson D, Glass KC, Hutton B, Shapiro S. Randomized controlled trials of aprotinin in cardiac surgery: Could clinical equipoise have stopped the bleeding? Clin Trials 2005; 2: 218-29.
2. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354: 353-65.
3. Karkouti K, Beattie WS, Dattilo KM, McCluskey SA, Ghannam M, Hamdy A, Wijeysundera DN, Fedorko L, Yau TM. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion 2006; 46: 327-38.
4. Spiess BD. Transfusion of blood products affects outcome in cardiac surgery. Semin Cardiothorac Vasc Anesth 2004; 8: 267-81.
5. Karkouti K, Wijeysundera DN, Yau TM, Beattie WS, Abdelnaem E, McCluskey SA, Ghannam M, Yeo E, Djaiani G, Karski J. The independent association of massive blood loss with mortality in cardiac surgery. Transfusion 2004; 44: 1453-62.
6. Levi M, Cromheecke ME, de Jonge E, Prins MH, de Mol BJ, Briet E, Buller HR. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: A meta-analysis of clinically relevant endpoints. Lancet 1999; 354: 1940-7.
7. Henry DA, Moxey AJ, Carless PA, O'Connell D, McClelland B, Henderson KM, Sly K, Laupacis A, Fergusson D. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2001: CD001886.
8. Ioannidis JP, Haidich AB, Pappa M, Pantazis N, Kokori SI, Tektonidou MG, Contopoulos-Ioannidis DG, Lau J. Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA 2001; 286: 821-30.
9. Carless PA, Moxey AJ, Stokes BJ, Henry DA. Are antifibrinolytic drugs equivalent in reducing blood loss and transfusion in cardiac surgery? A meta-analysis of randomized head-to-head trials. BMC Cardiovasc Disord 2005; 5: 19.
10. Brown JR, Birkmeyer NJ, O'Connor GT. Aprotinin in cardiac surgery. N Engl J Med 2006; 354: 1953-7.
11. Papanikolaou PN, Christidi GD, Ioannidis JP. Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. CMAJ 2006; 174: 635-41.
12. Ferraris VA, Bridges CR, Anderson RP. Aprotinin in cardiac surgery. N Engl J Med 2006; 354: 1953-7.
13. Wijeysundera DN, Rao V, Beattie WS, Ivanov J, Karkouti K. Evaluating surrogate measures of renal dysfunction after cardiac surgery. Anesth Analg 2003; 96: 1265-73.
14. http://www.fda.gov/bbs/topics/NEWS/NEW00453.html. (accessed on June 5, 2006).